Vir Biotechnology (VIR) Financials

$9.38 +0.19 (+2.07%)

Closing price 05/26/2026 04:00 PM Eastern

Extended Trading

$9.28 -0.10 (-1.07%)

As of 08:54 AM Eastern

Annual Income Statements for Vir Biotechnology

This table shows Vir Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-70	-116	-175	-299	529	516	-615	-522	-438
Consolidated Net Income / (Loss)	-70	-116	-175	-299	529	516	-615	-522	-438
Net Income / (Loss) Continuing Operations	-70	-116	-175	-299	529	516	-615	-522	-438
Total Pre-Tax Income	-81	-116	-175	-299	550	754	-628	-523	-438
Total Operating Income	-81	-119	-178	-297	421	833	-684	-587	-479
Total Gross Profit	2.71	11	8.09	76	1,030	1,469	83	73	69
Total Revenue	2.71	11	8.09	76	1,095	1,616	86	74	69
Operating Revenue	2.71	11	8.09	76	1,095	1,616	86	74	69
Total Cost of Revenue	0.00	0.00	0.00	0.00	66	146	2.77	0.85	0.03
Operating Cost of Revenue	-	-	0.00	0.00	66	146	2.77	0.85	0.03
Total Operating Expenses	84	129	186	373	609	636	768	661	548
Selling, General & Admin Expense	22	29	38	71	161	162	174	119	92
Research & Development Expense	63	100	148	302	448	475	580	506	456
Restructuring Charge	-	-	-	-	-	0.00	14	35	-0.18
Total Other Income / (Expense), net	0.72	2.33	3.45	-1.63	129	-79	56	64	42
Interest & Investment Income	0.64	-	-	-	0.44	28	87	72	40
Other Income / (Expense), net	0.08	-0.21	-5.06	-4.47	129	-107	-31	-7.75	1.32
Income Tax Expense	-11	-0.48	0.15	0.05	21	238	-13	-1.15	0.22
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	0.00	0.00	-0.06	0.00	0.00
Basic Earnings per Share	($32.45)	($15.12)	($5.76)	($2.51)	$4.07	$3.89	($4.59)	($3.83)	($3.16)
Weighted Average Basic Shares Outstanding	2.15M	7.67M	30.35M	119.16M	129.88M	132.61M	134.13M	136.25M	138.52M
Diluted Earnings per Share	($32.45)	($15.12)	($5.76)	($2.51)	$3.96	$3.83	($4.59)	($3.83)	($3.16)
Weighted Average Diluted Shares Outstanding	2.15M	7.67M	30.35M	119.16M	133.44M	134.81M	134.13M	136.25M	138.52M
Weighted Average Basic & Diluted Shares Outstanding	2.15M	7.67M	30.35M	119.16M	132.30M	133.53M	135.03M	137.14M	139.52M

This table shows Vir Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-163	-116	-65	-138	-214	-105	-121	-111	-163	-43	-126
Consolidated Net Income / (Loss)	-163	-116	-65	-138	-214	-105	-121	-111	-163	-43	-126
Net Income / (Loss) Continuing Operations	-163	-116	-65	-138	-214	-105	-121	-111	-163	-43	-126
Total Pre-Tax Income	-167	-121	-65	-140	-214	-105	-121	-111	-163	-43	-126
Total Operating Income	-187	-139	-80	-159	-231	-117	-140	-118	-173	-48	-132
Total Gross Profit	2.60	16	56	3.02	2.33	12	3.03	1.20	0.00	64	0.00
Total Revenue	2.64	17	56	3.08	2.38	12	3.03	1.21	0.00	64	0.00
Total Cost of Revenue	0.04	0.80	0.06	0.05	0.05	0.68	0.00	0.01	0.00	0.02	0.00
Total Operating Expenses	189	155	136	162	234	129	143	120	174	112	132
Selling, General & Admin Expense	41	41	36	30	26	27	24	22	22	24	23
Research & Development Expense	145	109	100	105	195	106	119	98	151	88	109
Restructuring Charge	3.37	-	-0.05	26	13	-	-0.01	-0.17	0.00	-	0.00
Total Other Income / (Expense), net	20	18	15	19	18	12	19	7.63	10	4.86	6.77
Interest & Investment Income	22	-	21	19	18	-	12	11	9.36	7.80	7.19
Other Income / (Expense), net	-1.83	-2.48	-6.20	-0.11	0.24	-1.68	6.31	-3.16	1.11	-2.94	-0.42
Income Tax Expense	-3.21	-4.78	0.28	-1.51	0.18	-0.09	0.02	0.17	0.17	-0.14	0.17
Basic Earnings per Share	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)	($0.80)	($1.17)	($0.31)	($0.85)
Weighted Average Basic Shares Outstanding	134.29M	134.13M	135.28M	136.22M	136.65M	136.25M	137.47M	138.45M	138.93M	138.52M	147.36M
Diluted Earnings per Share	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)	($0.80)	($1.17)	($0.31)	($0.85)
Weighted Average Diluted Shares Outstanding	134.29M	134.13M	135.28M	136.22M	136.65M	136.25M	137.47M	138.45M	138.93M	138.52M	147.36M
Weighted Average Basic & Diluted Shares Outstanding	134.52M	135.03M	136.06M	136.64M	137.72M	137.14M	138.24M	138.92M	139.13M	139.52M	168.65M

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	175	-130	63	329	-88	505	-607	57	-78
Net Cash From Operating Activities	-66	-94	-130	-191	-48	1,663	-779	-446	-392
Net Cash From Continuing Operating Activities	-66	-94	-130	-191	-48	1,663	-778	-446	-392
Net Income / (Loss) Continuing Operations	-70	-116	-175	-299	529	516	-615	-522	-438
Consolidated Net Income / (Loss)	-70	-116	-175	-299	529	516	-615	-522	-438
Depreciation Expense	0.26	1.62	3.29	4.40	5.28	6.78	19	15	12
Amortization Expense	0.18	0.81	1.04	2.59	0.29	-8.94	-8.71	5.40	9.47
Non-Cash Adjustments To Reconcile Net Income	9.10	7.35	24	33	-61	500	159	139	47
Changes in Operating Assets and Liabilities, net	-6.06	12	17	68	-521	650	-333	-83	-22
Net Cash From Investing Activities	-30	-60	-256	-9.86	-141	-1,193	165	499	310
Net Cash From Continuing Investing Activities	-30	-60	-256	-9.86	-141	-1,193	165	499	310
Purchase of Property, Plant & Equipment	-2.74	-9.94	-8.94	-6.55	-22	-68	-22	-7.30	-4.83
Purchase of Investments	0.00	-123	-644	-404	-420	-1,477	-2,016	-1,235	-886
Sale of Property, Plant & Equipment	0.00	0.03	0.00	0.00	-	0.00	0.00	3.37	0.25
Sale and/or Maturity of Investments	0.00	73	397	400	301	352	2,202	1,739	1,201
Net Cash From Financing Activities	271	25	449	529	100	35	7.48	4.39	3.79
Net Cash From Continuing Financing Activities	271	25	449	529	100	35	7.48	4.39	3.79
Repayment of Debt	0.00	0.00	3.27	-	-	-0.26	-0.29	-0.17	-0.36
Issuance of Common Equity	0.00	0.00	126	530	88	32	4.28	3.76	2.80
Other Financing Activities, net	0.00	11	2.23	-0.44	13	3.34	3.48	0.79	1.35

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-215	-211	-81	137	-53	54	49	-62	-127	62	42
Net Cash From Operating Activities	-156	-108	-109	-78	-171	-88	-78	-120	-168	-26	-132
Net Cash From Continuing Operating Activities	-156	-108	-109	-78	-171	-88	-78	-120	-168	-26	-132
Net Income / (Loss) Continuing Operations	-163	-116	-65	-138	-214	-105	-121	-111	-163	-43	-126
Consolidated Net Income / (Loss)	-163	-116	-65	-138	-214	-105	-121	-111	-163	-43	-126
Depreciation Expense	4.59	4.48	4.52	4.26	2.90	2.89	2.87	2.92	3.00	2.90	2.81
Amortization Expense	2.31	1.35	0.24	2.64	0.35	2.17	4.09	2.52	1.32	1.55	0.39
Non-Cash Adjustments To Reconcile Net Income	31	35	33	56	21	32	9.83	10	12	15	13
Changes in Operating Assets and Liabilities, net	-30	-33	-82	-2.54	18	-20	26	-25	-21	-2.84	-23
Net Cash From Investing Activities	-59	-105	28	212	119	141	127	56	40	87	12
Net Cash From Continuing Investing Activities	-59	-105	28	212	119	141	127	56	40	87	12
Purchase of Property, Plant & Equipment	-3.71	-1.54	-1.87	-0.67	-2.36	-2.41	-1.63	-2.54	-0.32	-0.35	-0.39
Purchase of Investments	-503	-819	-563	-271	-240	-161	-174	-192	-264	-256	-158
Sale of Property, Plant & Equipment	-	-	0.53	0.38	0.01	2.46	0.28	0.05	0.04	-0.11	0.00
Sale and/or Maturity of Investments	448	716	593	483	362	301	302	251	305	343	171
Net Cash From Financing Activities	0.28	1.68	0.15	2.94	0.03	1.26	0.60	2.05	0.10	1.04	163
Net Cash From Continuing Financing Activities	0.28	1.68	0.15	2.94	0.03	1.26	0.60	2.05	0.10	1.04	163
Issuance of Common Equity	-	1.58	-	2.60	-	1.16	0.00	-	-	1.04	162
Other Financing Activities, net	0.28	0.29	0.15	0.34	0.03	0.27	0.60	0.65	0.10	0.00	0.17

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	192	512	919	1,954	2,802	1,919	1,399	1,003
Total Current Assets	118	403	772	1,563	2,519	1,588	1,042	514
Cash & Equivalents	48	109	437	348	849	242	223	232
Restricted Cash	11	6.18	7.99	8.59	13	13	89	1.92
Short-Term Investments	51	274	300	360	1,553	1,281	682	235
Prepaid Expenses	8.58	13	28	73	104	53	48	45
Plant, Property, & Equipment, net	12	16	18	43	106	96	63	56
Total Noncurrent Assets	62	93	128	349	177	235	293	433
Long-Term Investments	0.00	24	0.00	201	24	105	190	315
Goodwill	17	17	17	17	17	17	17	17
Intangible Assets	37	36	34	33	33	23	8.12	7.85
Other Noncurrent Operating Assets	6.67	8.55	71	90	97	84	72	87
Other Noncurrent Nonoperating Assets	1.00	7.30	6.92	7.01	6.66	6.45	6.36	6.96
Total Liabilities & Shareholders' Equity	192	512	919	1,954	2,802	1,919	1,399	1,003
Total Liabilities	62	88	202	522	724	329	248	238
Total Current Liabilities	40	59	99	341	511	175	120	93
Accounts Payable	6.47	5.88	5.08	6.52	6.42	6.33	5.08	9.80
Accrued Expenses	15	26	77	237	489	104	99	83
Total Noncurrent Liabilities	22	29	103	181	213	153	129	145
Other Noncurrent Operating Liabilities	11	13	96	159	160	153	129	145
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-179	424	717	1,432	2,078	1,590	1,150	765
Total Preferred & Common Equity	-179	424	717	1,432	2,078	1,590	1,150	765
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-179	424	717	1,432	2,078	1,590	1,150	765
Common Stock	15	793	1,385	1,572	1,710	1,829	1,912	1,965
Retained Earnings	-194	-369	-667	-139	377	-238	-760	-1,198
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.60	-1.28	-1.10	-9.12	-0.82	-1.72	-2.06

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	2,696	2,666	2,244	2,045	1,794	1,670	1,498	1,308	1,193	1,019	1,026
Total Current Assets	2,414	2,359	1,946	1,769	1,213	1,206	1,047	932	736	546	523
Cash & Equivalents	964	825	667	452	161	297	168	274	211	170	274
Restricted Cash	13	11	13	13	13	14	90	88	88	2.22	1.93
Short-Term Investments	1,360	1,425	1,180	1,244	989	854	746	528	395	336	202
Prepaid Expenses	54	98	86	59	50	41	43	42	41	37	45
Plant, Property, & Equipment, net	100	104	104	99	92	66	65	62	61	58	53
Total Noncurrent Assets	182	204	193	176	488	398	386	314	396	416	449
Long-Term Investments	34	49	52	40	360	280	271	218	286	304	333
Goodwill	17	17	17	17	17	17	17	17	17	17	17
Intangible Assets	33	33	26	25	22	19	19	8.07	8.00	7.92	7.78
Other Noncurrent Operating Assets	91	98	92	87	83	76	72	64	78	80	85
Other Noncurrent Nonoperating Assets	7.28	6.74	6.74	7.06	6.43	6.37	6.38	6.27	6.96	6.96	6.96
Total Liabilities & Shareholders' Equity	2,696	2,666	2,244	2,045	1,794	1,670	1,498	1,308	1,193	1,019	1,026
Total Liabilities	546	695	434	370	247	236	258	264	245	223	213
Total Current Liabilities	308	485	226	165	94	96	117	137	105	75	74
Accounts Payable	2.72	12	12	3.63	7.11	4.39	7.31	3.73	12	6.85	5.45
Accrued Expenses	283	456	198	146	72	75	95	104	83	68	68
Total Noncurrent Liabilities	238	210	208	205	153	139	140	127	140	148	139
Other Noncurrent Operating Liabilities	165	153	155	152	151	139	140	127	140	139	139
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,150	1,971	1,810	1,675	1,547	1,434	1,241	1,044	947	796	813
Total Preferred & Common Equity	2,150	1,971	1,810	1,675	1,547	1,434	1,241	1,044	947	796	813
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,150	1,971	1,810	1,675	1,547	1,434	1,241	1,044	947	796	813
Common Stock	1,683	1,738	1,772	1,799	1,853	1,878	1,895	1,927	1,941	1,953	2,140
Retained Earnings	479	236	42	-122	-303	-441	-655	-881	-992	-1,155	-1,323
Accumulated Other Comprehensive Income / (Loss)	-12	-3.22	-2.90	-1.90	-2.40	-2.88	1.13	-1.98	-2.22	-1.91	-3.48

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	293.94%	-24.16%	843.86%	1,334.39%	47.51%	-94.67%	-13.90%	-7.61%
EBITDA Growth	0.00%	-43.83%	-53.42%	-64.78%	288.46%	30.47%	-197.29%	18.38%	20.54%
EBIT Growth	0.00%	-46.05%	-53.94%	-64.69%	282.24%	32.19%	-198.48%	16.82%	19.65%
NOPAT Growth	0.00%	-45.64%	-49.95%	-66.86%	294.58%	40.84%	-184.08%	14.20%	18.37%
Net Income Growth	0.00%	-65.90%	-50.74%	-70.98%	276.98%	-2.41%	-219.25%	15.14%	16.09%
EPS Growth	0.00%	53.41%	61.90%	56.42%	257.77%	-3.28%	-219.84%	16.56%	17.49%
Operating Cash Flow Growth	0.00%	-41.75%	-37.77%	-47.29%	75.08%	3,595.04%	-146.82%	42.69%	12.23%
Free Cash Flow Firm Growth	0.00%	0.00%	-10.48%	-50.45%	26.71%	1,241.11%	-154.66%	43.80%	24.47%
Invested Capital Growth	0.00%	0.00%	-47.37%	-322.41%	2,183.45%	-172.49%	84.44%	56.85%	-2.16%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	1.00%	285.18%	-32.08%	-27.46%	-5.61%	312.49%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-15.57%	674.37%	-49.91%	5.10%	3.67%	12.85%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-15.28%	639.22%	-49.56%	3.55%	3.67%	12.45%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-17.69%	322.77%	-53.46%	1.65%	3.59%	12.62%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-16.31%	616.60%	-54.86%	-2.39%	2.13%	12.34%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-162.44%	540.00%	-55.31%	-2.68%	2.30%	12.71%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-7.80%	-29.21%	65.35%	1.68%	-22.50%	4.35%	13.62%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	29.04%	-1.61%	-20.18%	4.91%	16.55%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-439.99%	6,607.20%	-46.37%	29.72%	40.16%	-5.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	93.99%	90.94%	96.79%	98.86%	99.96%
EBITDA Margin	-2,990.47%	-1,091.83%	-2,208.65%	-385.58%	50.66%	44.81%	-817.40%	-774.82%	-666.40%
Operating Margin	-3,009.49%	-1,112.60%	-2,199.72%	-388.88%	38.41%	51.56%	-794.04%	-791.27%	-699.18%
EBIT Margin	-3,006.43%	-1,114.59%	-2,262.27%	-394.73%	50.15%	44.94%	-829.87%	-801.72%	-697.25%
Profit (Net Income) Margin	-2,579.47%	-1,086.28%	-2,158.98%	-391.09%	48.25%	31.92%	-713.76%	-703.40%	-638.87%
Tax Burden Percent	86.48%	99.59%	100.09%	100.02%	96.14%	68.39%	97.92%	99.78%	100.05%
Interest Burden Percent	99.22%	97.86%	95.35%	99.06%	100.08%	103.87%	87.84%	87.93%	91.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	3.86%	31.61%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-799.77%	-785.73%	0.00%	167.71%	817.53%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-739.69%	-766.54%	0.00%	152.82%	820.73%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	621.43%	722.66%	0.00%	-118.51%	-788.14%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-178.34%	-63.07%	-52.36%	49.20%	29.39%	-33.54%	-38.09%	-45.73%
Cash Return on Invested Capital (CROIC)	0.00%	-999.77%	-723.66%	0.00%	-24.97%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-62.06%	-52.02%	-42.14%	38.24%	30.54%	-30.30%	-35.86%	-39.81%
Return on Assets (ROA)	0.00%	-60.48%	-49.65%	-41.75%	36.80%	21.69%	-26.06%	-31.46%	-36.47%
Return on Common Equity (ROCE)	0.00%	245.88%	-27.87%	-52.36%	49.20%	29.39%	-33.54%	-38.09%	-45.73%
Return on Equity Simple (ROE_SIMPLE)	0.00%	64.68%	-41.20%	-41.66%	36.92%	24.82%	-38.68%	-45.37%	0.00%
Net Operating Profit after Tax (NOPAT)	-57	-83	-125	-208	405	570	-479	-411	-336
NOPAT Margin	-2,106.64%	-778.82%	-1,539.80%	-272.22%	36.93%	35.26%	-555.83%	-553.89%	-489.42%
Net Nonoperating Expense Percent (NNEP)	0.00%	-60.08%	-19.19%	-15.73%	14.89%	-3.20%	-6.65%	-7.86%	-10.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	27.42%	-30.12%	-35.24%	-43.84%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	6.01%	9.06%	3.21%	1.14%	0.04%
SG&A Expenses to Revenue	801.07%	273.07%	464.69%	92.89%	14.68%	10.01%	202.41%	160.41%	134.30%
R&D to Revenue	2,308.42%	939.53%	1,835.03%	395.99%	40.90%	29.38%	672.69%	682.57%	665.10%
Operating Expenses to Revenue	3,109.49%	1,212.60%	2,299.72%	488.88%	55.58%	39.39%	890.83%	890.14%	799.14%
Earnings before Interest and Taxes (EBIT)	-81	-119	-183	-301	549	726	-715	-595	-478
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-81	-116	-179	-294	555	724	-704	-575	-457
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	3.25	4.76	3.83	1.62	0.85	0.88	1.10
Price to Tangible Book Value (P/TBV)	0.00	0.00	3.71	5.12	3.97	1.66	0.87	0.90	1.13
Price to Revenue (P/Rev)	52.75	13.39	170.46	44.67	5.00	2.09	15.70	13.62	12.24
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	10.37	6.53	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	9.65%	15.31%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	16.50	89.03	0.00	9.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	32.13	120.32	35.06	4.16	0.58	0.00	0.00	0.81
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	8.22	1.29	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	8.30	1.28	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	11.28	1.63	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.02	0.01	0.00	0.00	0.00	0.01	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.84	-0.94	-1.01	-0.78	-0.96	-1.12	-1.03	-1.03
Leverage Ratio	0.00	1.47	1.27	1.25	1.34	1.36	1.29	1.21	1.25
Compound Leverage Factor	0.00	1.44	1.21	1.24	1.34	1.41	1.13	1.06	1.15
Debt to Total Capital	0.00%	0.00%	1.90%	1.46%	0.00%	0.00%	0.00%	1.38%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	1.90%	1.46%	0.00%	0.00%	0.00%	1.38%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	237.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-137.87%	98.10%	98.54%	100.00%	100.00%	100.00%	98.62%	100.00%
Debt to EBITDA	0.00	0.00	-0.05	-0.04	0.00	0.00	0.00	-0.03	0.00
Net Debt to EBITDA	0.00	0.00	2.27	2.49	0.00	0.00	0.00	2.03	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	-0.07	-0.05	0.00	0.00	0.00	-0.04	0.00
Net Debt to NOPAT	0.00	0.00	3.26	3.53	0.00	0.00	0.00	2.84	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	-1.53	8.02	9.00	8.43	5.27	1.99	1.12	-0.55
Noncontrolling Interest Sharing Ratio	0.00%	237.87%	55.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	2.95	6.81	7.80	4.58	4.93	9.05	8.71	5.54
Quick Ratio	0.00	2.47	6.48	7.44	4.34	4.70	8.68	7.57	5.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-104	-115	-173	-127	1,444	-789	-444	-335
Operating Cash Flow to CapEx	-2,420.90%	-949.51%	-1,450.02%	-2,915.57%	-218.13%	2,445.74%	-3,610.00%	-11,360.45%	-8,556.04%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.06	0.02	0.11	0.76	0.68	0.04	0.04	0.06
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.87	0.57	4.46	36.05	21.77	0.85	0.93	1.15
Accounts Payable Turnover	0.00	0.00	0.00	0.00	11.36	22.61	0.43	0.15	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	32.14	16.14	841.94	2,465.37	104,474.23
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-32.14	-16.14	-841.94	-2,465.37	-104,474.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	21	11	-24	507	-367	-57	-25	-25
Invested Capital Turnover	0.00	1.03	0.51	-11.41	4.54	23.19	-0.41	-1.81	-2.75
Increase / (Decrease) in Invested Capital	0.00	21	-9.84	-35	531	-874	310	32	-0.53
Enterprise Value (EV)	0.00	343	974	2,677	4,562	931	-288	-158	55
Market Capitalization	143	143	1,379	3,411	5,480	3,369	1,353	1,011	839
Book Value per Share	$0.00	($23.37)	$3.87	$5.63	$10.94	$15.61	$11.82	$8.35	$5.50
Tangible Book Value per Share	$0.00	($30.40)	$3.39	$5.23	$10.56	$15.24	$11.53	$8.17	$5.32
Total Capital	0.00	130	432	727	1,432	2,078	1,590	1,166	765
Total Debt	0.00	0.00	8.20	11	0.00	0.00	0.00	16	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-109	-406	-734	-918	-2,439	-1,641	-1,169	-784
Capital Expenditures (CapEx)	2.74	9.91	8.94	6.55	22	68	22	3.93	4.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-31	-38	-61	505	-407	-123	-56	-48
Debt-free Net Working Capital (DFNWC)	0.00	78	352	684	1,222	2,008	1,413	939	421
Net Working Capital (NWC)	0.00	78	344	673	1,222	2,008	1,413	923	421
Net Nonoperating Expense (NNE)	13	33	50	91	-124	54	136	111	102
Net Nonoperating Obligations (NNO)	0.00	-109	-413	-741	-925	-2,445	-1,647	-1,175	-790
Total Depreciation and Amortization (D&A)	0.43	2.43	4.34	6.99	5.57	-2.16	11	20	21
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-293.67%	-465.06%	-79.81%	46.09%	-25.17%	-142.56%	-75.30%	-69.54%
Debt-free Net Working Capital to Revenue	0.00%	729.99%	4,350.38%	895.53%	111.52%	124.28%	1,639.38%	1,265.22%	614.48%
Net Working Capital to Revenue	0.00%	729.99%	4,249.03%	881.65%	111.52%	124.28%	1,639.38%	1,243.58%	614.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($5.76)	($2.51)	$4.07	$3.89	($4.59)	($3.83)	($3.16)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	109.80M	127.84M	129.88M	132.61M	134.13M	136.25M	138.52M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($5.76)	($2.51)	$3.96	$3.83	($4.59)	($3.83)	($3.16)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	109.80M	127.84M	133.44M	134.81M	134.13M	136.25M	138.52M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($5.76)	($2.51)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	30.35M	119.16M	132.30M	133.53M	135.03M	137.14M	139.52M
Normalized Net Operating Profit after Tax (NOPAT)	-57	-83	-125	-208	405	570	-470	-387	-336
Normalized NOPAT Margin	-2,106.64%	-778.82%	-1,539.80%	-272.22%	36.93%	35.26%	-544.82%	-520.88%	-489.61%
Pre Tax Income Margin	-2,982.87%	-1,090.78%	-2,157.08%	-391.02%	50.19%	46.68%	-728.93%	-704.95%	-638.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	139,517,278.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	139,517,278.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.90
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-99.30%	-66.03%	-10.45%	-19.02%	-9.81%	-26.29%	-94.62%	-60.52%	-100.00%	419.72%	-100.00%
EBITDA Growth	-187.74%	21.80%	51.54%	30.63%	-25.41%	16.13%	-54.89%	23.51%	26.25%	59.20%	-2.56%
EBIT Growth	-190.48%	15.68%	47.55%	28.06%	-22.54%	16.02%	-54.42%	23.41%	25.42%	57.20%	0.39%
NOPAT Growth	-183.27%	7.63%	44.14%	26.28%	-23.87%	15.73%	-74.26%	25.35%	25.02%	59.09%	5.20%
Net Income Growth	-193.21%	-14.14%	53.69%	28.95%	-30.78%	9.82%	-85.31%	19.82%	23.66%	58.96%	-3.91%
EPS Growth	-193.85%	-16.22%	54.72%	29.66%	-27.87%	10.47%	-83.33%	21.57%	25.00%	59.74%	3.41%
Operating Cash Flow Growth	-232.17%	-407.26%	13.03%	80.00%	-10.04%	18.80%	28.59%	-54.43%	2.28%	70.47%	-69.47%
Free Cash Flow Firm Growth	-175.06%	-153.01%	-271.00%	49.78%	32.73%	71.90%	93.65%	70.04%	31.28%	71.17%	-425.41%
Invested Capital Growth	67.59%	84.44%	105.23%	83.84%	49.32%	56.85%	-392.21%	-124.98%	42.27%	-2.16%	89.82%
Revenue Q/Q Growth	-30.50%	536.11%	235.83%	-94.55%	-22.60%	419.92%	-75.50%	-59.96%	-100.00%	0.00%	-100.00%
EBITDA Q/Q Growth	17.01%	25.32%	39.90%	-86.24%	-50.04%	50.06%	-10.99%	8.03%	-44.68%	72.38%	-179.02%
EBIT Q/Q Growth	14.54%	24.96%	39.02%	-83.97%	-45.57%	48.57%	-12.13%	8.75%	-41.76%	70.49%	-160.93%
NOPAT Q/Q Growth	13.22%	25.55%	42.39%	-98.09%	-45.81%	49.35%	-19.12%	15.14%	-46.47%	72.37%	-176.06%
Net Income Q/Q Growth	16.10%	29.03%	43.71%	-111.99%	-54.44%	51.06%	-15.66%	8.27%	-47.03%	73.69%	-192.84%
EPS Q/Q Growth	15.86%	29.51%	44.19%	-112.50%	-52.94%	50.64%	-14.29%	9.09%	-46.25%	73.50%	-174.19%
Operating Cash Flow Q/Q Growth	59.97%	30.74%	-1.36%	28.84%	-120.28%	48.89%	10.86%	-53.90%	-39.39%	84.56%	-411.62%
Free Cash Flow Firm Q/Q Growth	25.64%	-35.68%	-3.15%	51.74%	0.40%	43.32%	76.71%	-127.86%	-128.45%	76.22%	-324.47%
Invested Capital Q/Q Growth	25.71%	29.72%	131.67%	-197.75%	-132.91%	40.16%	-114.49%	24.74%	40.23%	-5.88%	78.63%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.56%	95.25%	99.90%	98.31%	97.90%	94.47%	100.00%	99.09%	0.00%	99.98%	0.00%
EBITDA Margin	-6,883.74%	-808.14%	-144.61%	-4,937.85%	-9,572.14%	-919.46%	-4,164.94%	-9,566.31%	0.00%	-72.17%	0.00%
Operating Margin	-7,075.86%	-828.12%	-142.05%	-5,158.70%	-9,718.66%	-946.74%	-4,602.47%	-9,754.28%	0.00%	-74.52%	0.00%
EBIT Margin	-7,145.02%	-842.87%	-153.05%	-5,162.15%	-9,708.70%	-960.30%	-4,394.36%	-10,014.25%	0.00%	-79.09%	0.00%
Profit (Net Income) Margin	-6,192.23%	-690.85%	-115.79%	-4,500.10%	-8,979.71%	-845.23%	-3,989.61%	-9,139.87%	0.00%	-66.74%	0.00%
Tax Burden Percent	98.07%	96.04%	100.42%	98.92%	100.08%	99.92%	100.01%	100.15%	100.10%	99.68%	100.14%
Interest Burden Percent	88.37%	85.34%	75.33%	88.13%	92.41%	88.09%	90.78%	91.13%	94.57%	84.66%	94.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-31.41%	-33.54%	-30.67%	-29.78%	-36.58%	-38.09%	-44.59%	-46.22%	-49.06%	-45.73%	-47.69%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-4,412.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-358.10%	-30.77%	-5.46%	-208.09%	-430.84%	-42.95%	-59.11%	-132.96%	0.00%	-4.52%	0.00%
Return on Assets (ROA)	-310.35%	-25.22%	-4.13%	-181.40%	-398.49%	-37.81%	-53.67%	-121.35%	0.00%	-3.81%	0.00%
Return on Common Equity (ROCE)	-31.41%	-33.54%	-30.67%	-29.78%	-36.58%	-38.09%	-44.59%	-46.22%	-49.06%	-45.73%	-47.69%
Return on Equity Simple (ROE_SIMPLE)	-35.86%	0.00%	-34.86%	-33.69%	-42.99%	0.00%	-55.34%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-131	-97	-56	-111	-162	-82	-98	-83	-121	-34	-93
NOPAT Margin	-4,953.10%	-579.68%	-99.43%	-3,611.09%	-6,803.06%	-662.72%	-3,221.73%	-6,828.00%	0.00%	-52.16%	0.00%
Net Nonoperating Expense Percent (NNEP)	-1.57%	-0.91%	-0.48%	-1.62%	-3.41%	-1.60%	-1.77%	-2.30%	-3.97%	-0.95%	-3.46%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.12%	-	-	-	-7.03%	-9.20%	-8.75%	-15.25%	-4.38%	-11.39%
Cost of Revenue to Revenue	1.44%	4.75%	0.10%	1.69%	2.10%	5.53%	0.00%	0.91%	0.00%	0.02%	0.00%
SG&A Expenses to Revenue	1,551.08%	245.54%	64.34%	984.23%	1,081.68%	216.17%	789.71%	1,835.50%	0.00%	36.72%	0.00%
R&D to Revenue	5,495.57%	649.11%	177.60%	3,418.31%	8,200.76%	857.31%	3,913.09%	8,032.04%	0.00%	137.38%	0.00%
Operating Expenses to Revenue	7,174.42%	923.36%	241.94%	5,257.01%	9,816.55%	1,041.22%	4,702.47%	9,853.38%	0.00%	174.10%	0.00%
Earnings before Interest and Taxes (EBIT)	-189	-141	-86	-159	-231	-119	-133	-122	-172	-51	-133
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-182	-136	-82	-152	-228	-114	-126	-116	-168	-46	-130
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.75	0.85	0.88	0.84	0.82	0.88	0.85	0.74	1.00	1.10	1.54
Price to Tangible Book Value (P/TBV)	0.77	0.87	0.90	0.87	0.85	0.90	0.87	0.76	1.03	1.13	1.59
Price to Revenue (P/Rev)	10.59	15.70	17.12	15.35	13.02	13.62	42.60	36.67	47.73	12.24	19.08
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	6.70
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.01	0.02	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.09	-1.12	-1.09	-1.04	-1.04	-1.03	-1.01	-1.02	-1.03	-1.03	-1.03
Leverage Ratio	1.24	1.29	1.27	1.21	1.22	1.21	1.20	1.20	1.24	1.25	1.26
Compound Leverage Factor	1.10	1.10	0.96	1.06	1.12	1.07	1.09	1.10	1.17	1.06	1.19
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	1.38%	1.65%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	1.38%	1.65%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	98.62%	98.35%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.03	-0.03	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	2.03	1.76	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.04	-0.04	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	2.84	2.41	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.65	2.98	3.71	3.24	2.06	2.25	1.49	0.86	0.56	0.85	1.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.72	9.05	12.90	12.51	8.94	8.71	6.79	7.01	7.25	5.54	7.11
Quick Ratio	10.28	8.68	12.22	11.94	7.81	7.57	5.84	5.77	6.73	5.03	6.48
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-300	-407	-420	-203	-202	-115	-27	-61	-139	-33	-140
Operating Cash Flow to CapEx	-4,195.72%	-7,031.07%	-8,169.53%	-27,124.39%	-7,293.92%	0.00%	-5,794.96%	-4,822.26%	-59,846.43%	-5,649.78%	-33,945.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.05	0.04	0.04	0.04	0.04	0.04	0.01	0.01	0.01	0.06	0.06
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.19	0.85	0.81	0.93	0.96	0.93	0.27	0.30	0.27	1.15	1.14
Accounts Payable Turnover	2.51	0.43	0.10	0.11	0.18	0.15	0.15	0.09	0.10	0.00	0.01
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	145.51	841.94	3,833.69	3,228.15	2,080.39	2,465.37	2,516.69	4,072.08	3,716.17	104,474.23	64,366.35
Cash Conversion Cycle (CCC)	-145.51	-841.94	-3,833.69	-3,228.15	-2,080.39	-2,465.37	-2,516.69	-4,072.08	-3,716.17	-104,474.23	-64,366.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-81	-57	18	-18	-41	-25	-53	-40	-24	-25	-5.39
Invested Capital Turnover	-0.72	-0.41	-0.49	-1.24	-1.28	-1.81	-1.20	-0.66	-0.51	-2.75	-2.25
Increase / (Decrease) in Invested Capital	170	310	364	92	40	32	-71	-22	17	-0.53	48
Enterprise Value (EV)	-491	-288	-160	-234	-252	-158	-202	-284	-20	55	439
Market Capitalization	1,258	1,353	1,363	1,211	1,023	1,011	889	697	793	839	1,250
Book Value per Share	$12.48	$11.82	$11.44	$10.54	$9.08	$8.35	$7.61	$6.85	$5.73	$5.50	$5.83
Tangible Book Value per Share	$12.16	$11.53	$11.15	$10.27	$8.82	$8.17	$7.43	$6.67	$5.55	$5.32	$5.65
Total Capital	1,675	1,590	1,547	1,434	1,241	1,166	1,061	947	796	765	813
Total Debt	0.00	0.00	0.00	0.00	0.00	16	18	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,749	-1,641	-1,523	-1,445	-1,276	-1,169	-1,090	-980	-813	-784	-811
Capital Expenditures (CapEx)	3.71	1.54	1.34	0.29	2.35	-0.05	1.35	2.49	0.28	0.46	0.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-106	-123	-44	-56	-74	-56	-77	-64	-38	-48	-29
Debt-free Net Working Capital (DFNWC)	1,604	1,413	1,119	1,109	930	939	812	631	470	421	449
Net Working Capital (NWC)	1,604	1,413	1,119	1,109	930	923	795	631	470	421	449
Net Nonoperating Expense (NNE)	33	19	9.22	27	52	23	23	28	42	9.38	33
Net Nonoperating Obligations (NNO)	-1,756	-1,647	-1,529	-1,451	-1,282	-1,175	-1,097	-987	-820	-790	-818
Total Depreciation and Amortization (D&A)	6.90	5.83	4.76	6.90	3.25	5.05	6.96	5.44	4.31	4.45	3.21
Debt-free, Cash-free Net Working Capital to Revenue	-88.90%	-142.56%	-55.36%	-70.59%	-94.22%	-75.30%	-370.99%	-334.39%	-230.24%	-69.54%	-43.95%
Debt-free Net Working Capital to Revenue	1,350.24%	1,639.38%	1,405.83%	1,406.40%	1,182.93%	1,265.22%	3,894.45%	3,319.48%	2,830.70%	614.48%	685.90%
Net Working Capital to Revenue	1,350.24%	1,639.38%	1,405.83%	1,406.40%	1,182.93%	1,243.58%	3,810.56%	3,319.48%	2,830.70%	614.48%	685.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)	($0.80)	($1.17)	($0.31)	($0.85)
Adjusted Weighted Average Basic Shares Outstanding	134.29M	134.13M	135.28M	136.23M	136.65M	136.25M	137.47M	138.45M	138.93M	138.52M	147.36M
Adjusted Diluted Earnings per Share	($1.22)	($0.86)	($0.48)	($1.02)	($1.56)	($0.77)	($0.88)	($0.80)	($1.17)	($0.31)	($0.85)
Adjusted Weighted Average Diluted Shares Outstanding	134.29M	134.13M	135.28M	136.23M	136.65M	136.25M	137.47M	138.45M	138.93M	138.52M	147.36M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	134.52M	135.03M	136.06M	136.64M	137.72M	137.14M	138.24M	138.92M	139.13M	139.52M	168.65M
Normalized Net Operating Profit after Tax (NOPAT)	-128	-97	-56	-93	-153	-82	-98	-83	-121	-34	-93
Normalized NOPAT Margin	-4,863.66%	-579.68%	-99.43%	-3,012.96%	-6,429.18%	-662.72%	-3,221.96%	-6,837.92%	0.00%	-52.16%	0.00%
Pre Tax Income Margin	-6,313.98%	-719.35%	-115.30%	-4,549.27%	-8,972.27%	-845.93%	-3,989.08%	-9,125.86%	0.00%	-66.96%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Vir Biotechnology (VIR) — key takeaways from the last four years of quarterly statements

Q4 2025 revenue rose to $64.31 million, with cost of revenue of only $15 thousand, producing a gross profit of $64.295 million and an essentially near-100% gross margin for the quarter.
The company maintains a solid liquidity cushion, with cash of $170.084 million and short-term investments of $336.429 million (as shown in the Q3 2025 balance sheet), plus other investments that support the balance sheet position.
Q4 2025 cash flow from investing activities shows a notable inflow (net investing cash flow of $86.651 million), helped by a $342.931 million sale/maturity of investments, which supports liquidity despite operating losses.
Net income for Q4 2025 narrowed to a loss of $42.923 million, versus a $104.589 million loss in Q4 2024, signaling an improvement in the bottom line despite ongoing losses.
Net cash from operating activities in Q4 2025 improved to a burn of $25.836 million (negative), down from the much larger year-ago cash burn, indicating reduced cash outflow from core operations in that quarter.
Revenue has been volatile across quarters (for example, Q3 2025 reported $0 in revenue while other quarters show varying amounts), suggesting uneven quarterly demand or recognition.
R&D expense remains a dominant operating cost in most periods (e.g., $88.349 million in Q4 2025), reflecting ongoing investment in development that weights heavily on profitability but is typical for a biotech portfolio.
Net income remains negative across the last four years, including -$42.923 million in Q4 2025 and larger losses in prior periods, underscoring persistent profitability challenges.
Operating income is negative in Q4 2025 (-$47.921 million), indicating ongoing operating losses even as topline strength appears episodic.
There is a history of cash burn from operations across many quarters (for example, CFO was -$167.57 million in Q3 2025 and -$87.64 million in Q4 2024), implying ongoing funding needs to support operations and R&D.

05/27/26 08:57 AM ETAI Generated. May Contain Errors.

Vir Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Vir Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Vir Biotechnology's net income appears to be on an upward trend, with a most recent value of -$437.99 million in 2025, rising from -$69.85 million in 2017. The previous period was -$521.96 million in 2024. See Vir Biotechnology's forecast for analyst expectations on what's next for the company.

Vir Biotechnology's total operating income in 2025 was -$479.33 million, based on the following breakdown:

Total Gross Profit: $68.53 million
Total Operating Expenses: $547.86 million

Over the last 8 years, Vir Biotechnology's total revenue changed from $2.71 million in 2017 to $68.56 million in 2025, a change of 2,431.6%.

Vir Biotechnology's total liabilities were at $237.55 million at the end of 2025, a 4.4% decrease from 2024, and a 285.4% increase since 2018.

In the past 7 years, Vir Biotechnology's cash and equivalents has ranged from $47.60 million in 2018 to $848.63 million in 2022, and is currently $232.19 million as of their latest financial filing in 2025.

Over the last 8 years, Vir Biotechnology's book value per share changed from 0.00 in 2017 to 5.50 in 2025, a change of 550.1%.

Related Companies

Financial statements for NASDAQ:VIR last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Financials

Financials Breakdown Chart

Key Financial Trends

Vir Biotechnology Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Financials

Annual Income Statements for Vir Biotechnology

Quarterly Income Statements for Vir Biotechnology

Annual Cash Flow Statements for Vir Biotechnology

Quarterly Cash Flow Statements for Vir Biotechnology

Annual Balance Sheets for Vir Biotechnology

Quarterly Balance Sheets for Vir Biotechnology

Annual Metrics And Ratios for Vir Biotechnology

Quarterly Metrics And Ratios for Vir Biotechnology

Financials Breakdown Chart

Key Financial Trends

Vir Biotechnology Financials - Frequently Asked Questions

When does Vir Biotechnology's fiscal year end?

How has Vir Biotechnology's net income changed over the last 8 years?

What is Vir Biotechnology's operating income?

How has Vir Biotechnology's revenue changed over the last 8 years?

How much debt does Vir Biotechnology have?

How much cash does Vir Biotechnology have?

How has Vir Biotechnology's book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools